Timing and safety of lung cancer surgery after SARS-CoV-2 infection: A multicenter retrospective study
- VernacularTitle:新型冠状病毒感染后肺癌手术时机及安全性的多中心回顾性研究
- Author:
Zhe HE
1
,
2
,
3
;
Qihang ZHU
4
;
Xianglin LI
2
,
5
;
Dezhao TANG
2
,
5
;
Junhan WU
2
,
5
;
Yizhang CHEN
2
,
5
;
Qibin CHEN
2
,
5
;
Qipeng ZHANG
3
,
6
;
Enwu XU
7
;
Haiping XIAO
4
;
Yong TANG
2
,
5
;
Guibin QIAO
2
,
5
Author Information
1. 1.Department of Thoracic Surgery, Guangdong Provincial People&rsquo
2. s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, P. R. China
3. 2. The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, P. R. China
4. Department of Cardiothoracic Surgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, 510080, P. R. China
5. Department of Thoracic Surgery, Guangdong Provincial People&rsquo
6. 3. Department of Thoracic Surgery, General Hospital of Southern Theater Command, PLA, Guangzhou, 510010, P. R. China
7. Department of Thoracic Surgery, General Hospital of Southern Theater Command, PLA, Guangzhou, 510010, P. R. China
- Publication Type:Journal Article
- Keywords:
Lung cancer surgery;
surgical timing;
safety;
COVID-19
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2023;30(07):945-949
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the timing and safety of limited-period lung cancer surgery in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods Clinical data of of patients infected with COVID-19 undergoing lung cancer surgery (an observation group) in the Department of Thoracic Surgery of Guangdong Provincial People's Hospital, the Department of Thoracic Surgery of General Hospital of Southern Theater Command of PLA, and the Department of Cardiothoracic Surgery of the First Affiliated Hospital of Guangdong Pharmaceutical University from December 2022 to January 2023 were retrospectively analyzed and compared with patients who underwent surgery during the same period but were not infected with COVID-19 (a control group), to explore the impact of COVID-19 infection on lung cancer surgery. Results We finally included 110 patients with 73 patients in the observation group (28 males and 45 females at age of 52.62±12.80 years) and 37 patients in the control group (22 males and 15 females at age of 56.84±11.14 years). The average operation time of the observation group was longer than that of the control group, and the incidence of anhelation was higher than that of the control group (P<0.05). There were no statistcal differences in blood loss, length of hospital stay, moderate or above fever rate, degree of cough and chest pain, or blood routine between the two groups. Conclusion It is safe and feasible to perform lung cancer surgery early after recovery for COVID-19 patients with lung cancer.
